The Conversation (0)
BioSyent released their financial results for the first quarter of 2017.
BioSyent (TSXV:RX) released their financial results for the first quarter of 2017.
As quoted in the press release:
“Q1 2017 marked BioSyent’s 27th consecutive profitable quarter” remarked René Goehrum, President and CEO of BioSyent. “While we maintained a healthy net profit margin, Q1 2017 growth was somewhat constrained, in part, by the lower inventory carrying levels of our Canadian pharmaceutical wholesaler customers which limited our sales of FeraMAX® during the quarter. As we continue to advance launch stage products in our Canadian hospital business, such as CYSVIEW® and the Aguettant System® line of pre-filled syringes, and with the bulk of our 2017 international pharmaceutical business coming in the last nine months of 2017, we are confident in the capacity of our product portfolio to deliver the growth that we expect in 2017. We are also encouraged by a recently announced national survey of physicians and pharmacists which recognized our FeraMAX® brand as the #1 recommended iron supplement brand in Canada for the second consecutive year.”
Click here to read the full press release.
Source: www.marketwired.com
